Pfizer - Sutent: clinical trials, ain't they a bitch!

Pfizer said two late-stage breast cancer trials involving its cancer drug Sutent failed to meet their goals and it has stopped a pivotal lung cancer trial of an experimental drug. Pfizer said outside monitors concluded that the Phase 3 trial of the lung cancer treatment, figitumumab, in patients with previously treated advanced non-small cell lung cancer was unlikely to show that the drug was effective. Pfizer said that it was “disappointed” in the Sutent trial results, but that it remained committed to exploring new therapies for breast cancer and to studying Sutent as a treatment for other solid tumors.

NYT